Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Agenus will release its second quarter 2022 financial results before the market opens on August 9, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus will release its second quarter 2022 financial results before the market opens on August 9, 2022.
The company will host a conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the conference via the provided dial-in numbers or through a webcast.
Agenus is focused on developing therapies for cancer and infections, leveraging a diverse portfolio of therapeutic approaches.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was +2.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET
LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will release its second quarter 2022 financial results before the market opens on Tuesday, August 9, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
Conference Call
Dial-in numbers: (646) 307-1963 (US-NY) or (800) 715-9871 (US & CA)
Event ID: 6683845
Webcast
A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/xh3u6boi.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Agenus Inc.
Ethan Lovell
Chief External Affairs & Communications Officer
339-927-1763
ethan.lovell@agenusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.